There are currently 56 active clinical trials seeking participants for Atopic Dermatitis research studies. The states with the highest number of trials for Atopic Dermatitis participants are California, Florida, Texas and Ontario.
A Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis
NCT06055361
Recruiting
The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of a single and multiple SC dose of BxC-I17e in patients with moderate to severe atopic dermatitis (AD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/07/2024
Locations: Arkansas Research Trials, North Little Rock, Arkansas +2 locations
Conditions: Atopic Dermatitis
Register for Updates
Molecular Signatures of Cutaneous Dupilumab Response
NCT05858619
Recruiting
This study examines the effect of IL4RA blockade with dupilumab on the immune cells of atopic dermatitis skin lesions.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/25/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Atopic Dermatitis
Register for Updates
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
NCT05635266
Recruiting
To collect, preserve, and/or distribute annotated biospecimens and associated medical data to institutionally approved, investigator-directed biomedical research to discover and develop new treatments, diagnostics, and preventative methods for specific and complex conditions.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
05/03/2024
Locations: Sanguine Biosciences, Waltham, Massachusetts
Conditions: Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo
Register for Updates
Phase 2 Trial of HY209gel in Atopic Dermatitis Patients
NCT06024499
Recruiting
This is a randomized, double-blind, placebo-controlled, multi-center, phase 2 study in patients with mild to moderate Atopic Dermatitis(AD), which consists of 2 parts.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/24/2024
Locations: Cahaba Dermatology Skin Health Center, Birmingham, Alabama +3 locations
Conditions: Atopic Dermatitis, Atopic Dermatitis Eczema, Atopic Dermatitis of Scalp
Register for Updates
Dupixent and Narrowband UVB for Atopic Dermatitis
NCT05285839
Recruiting
24 weeks open-label study with dupilumab and narrowband UVB phototherapy three times weekly for 12 weeks followed by 12 weeks of dupilumab monotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2024
Locations: Eczema Treatment Center of New Jersey, East Windsor, New Jersey
Conditions: Atopic Dermatitis
Register for Updates
10 Year Registry of Children (Ages 2-17 Years) With Eczema That Have Used Pimecrolimus
NCT00568997
Recruiting
This study will examine the risk of systemic malignancies in pediatric patients with atopic dermatitis exposed to Elidel 1% cream.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
02/22/2024
Locations: Registry, Philadelphia, Pennsylvania
Conditions: Atopic Dermatitis
Register for Updates
Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
NCT05694884
Recruiting
Multicenter, randomized, double-blind, placebo-controlled, parallel arm clinical study designed to evaluate the efficacy and safety of eblasakimab in participants with moderate-to-severe atopic dermatitis (AD) previously treated with dupilumab.The study consists of a 16-week treatment period and an 8-week follow-up period up to Week 24. Eligible participants will be randomized into one of the 2 treatment arms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/17/2024
Locations: ASLAN Investigative Site, Birmingham, Alabama +26 locations
Conditions: Atopic Dermatitis
Register for Updates
A Prospective Sample Collection Study Using Non-invasive Methods to Investigate Biomarkers in AD Patients
NCT04699695
Recruiting
This is a prospective, multicenter, sample collection study using DermTech's non-invasive skin collection kits to evaluate genomic biomarkers and microbiome information from pediatric and adult subjects with atopic dermatitis(AD). Samples collected will be analyzed to detect gene signatures and microbiome populations associated with AD and sub-populations of AD.
Gender:
ALL
Ages:
1 year and above
Trial Updated:
07/25/2022
Locations: Orit Markowitz, New York, New York +1 locations
Conditions: Atopic Dermatitis
Register for Updates